Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Olema Pharmaceuticals (OLMA – Research Report) and keeping the price ...

Inhibition of CDK6 may prevent arteriovenous malformations in hereditary hemorrhagic telangiectasia by regulating endothelial ...

A drug commonly used to treat breast cancer might be able to help people living with hereditary hemorrhagic telangiectasia (HHT) ? a rare genetic bleeding condition that causes enlargements and ...

VERITAC-2: Phase 3 monotherapy clinical trial in patients with metastatic breast cancer (ClinicalTrials.gov Identifier: NCT05654623) TACTIVE-U: Phase 1b/2 combination umbrella trial evaluating ...

Degradation of LRRK2 by ARV-102 induces changes in pathway (lysosomal and inflammation) biomarkers in the CSF of NHPs, which has not previously been demonstrated by kinase inhibitors of LRRK2.

As the decade progressed, other novel targeted agents, including lapatinib and bevacizumab were developed to disrupt additional growth signalling pathways in certain breast cancer subtypes.

We are conducting clinical trials to evaluate the use of ribociclib in combination with fulvestrant and ... of LABC in New York women with the goal of translating the Akt/mTOR pathway to treatment.

In fact, Wilkinson hopes an agreement between the Pathways Alliance consortium, Ottawa and Alberta can soon be reached to get one of the world’s largest carbon capture networks moving ...

This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...

“Therefore, I think it is important for us to then think … how do we create a lot more choices, a lot more flexible pathways to cater to the needs of the different students and also to meet ...

The proposed pathway would cross through the VIA Rail station property. However, staff say it's pausing the EA study because VIA Rail's future redevelopment plans for the site are unknown.